General Information of Drug (ID: DM0OEGV)

Drug Name
NAPHTHYRIDINONE Drug Info
Synonyms
NAPHTHYRIDINONE; CHEMBL204232; N-[3-Acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide; N-(3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl)acetamide; SCHEMBL762298; VHSIAYLBCLUAFT-UHFFFAOYSA-N
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11386747
TTD Drug ID
DM0OEGV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Guanfacine extended release DMB1CZ8 Attention deficit hyperactivity disorder 6A05.Z Approved [3]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [4]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [5]
KHK-6188 DMF6CTI Neuropathic pain 8E43.0 Phase 2 [6]
LY-2828360 DMO8IEZ Pain MG30-MG3Z Phase 2 [6]
APD371 DM3XT5V Crohn disease DD70 Phase 2 [7]
S-777469 DMZGNOJ Atopic dermatitis EA80 Phase 2 [8]
842166X DMOV0AP Pain MG30-MG3Z Phase 2 [9]
Beta-caryophyllene DM7583A Pain MG30-MG3Z Phase 2 [10]
Vicasinabin DMF16CU Diabetic retinopathy 9B71.0 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [12]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [4]
Orlistat DMRJSP8 Obesity 5B81 Approved [13]
SR141716A DMCO5JZ Obesity 5B81 Approved [14]
Tebipenem DMVSX6O Urinary tract infection GC08 Phase 3 [15]
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [16]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [5]
SR-147778 DMNAECP Obesity 5B81 Phase 2 [17]
Nimacimab DM21Z68 Diabetic nephropathy GB61.Z Phase 2 [18]
AEF0117 DMQ1GH4 Marijuana use disorder 6C41 Phase 2 [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Inhibitor [1]
Cannabinoid receptor 2 (CB2) TTMSFAW CNR2_HUMAN Inhibitor [2]

References

1 Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
2 Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):681-5.
3 Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
4 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
5 Company report (Gwpharm)
6 Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
9 The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
10 The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
11 Clinical pipeline report, company report or official report of Roche
12 Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
13 Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
14 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
15 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
16 Clinical pipeline report, company report or official report of AstraZeneca (2009).
17 Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
18 Clinical pipeline report, company report or official report of Bird Rock Bio.
19 Clinical pipeline report, company report or official report of Affimed Therapeutics.